Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients

NCT02829008 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: low-dose-bevacizumab/pemetrexed
DRUG: Treatment of physician's choice

Sponsor

Chinese Academy of Medical Sciences